title: Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding.
abstract: This study was designed 1) to examine the effects of blood-brain barrier (BBB) permeability [quantified as permeability-surface area product (PS)], unbound fraction in plasma (f(u,plasma)), and brain tissue (f(u,brain)) on the time to reach equilibrium between brain and plasma and 2) to investigate the drug discovery strategies to design and select compounds that can rapidly penetrate the BBB and distribute to the site of action. The pharmacokinetics of seven model compounds: caffeine, CP-141938 [methoxy-3-[(2-phenyl-piperadinyl-3-amino)-methyl]-phenyl-N-methyl-methane-sulfonamide], fluoxetine, NFPS [N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine], propranolol, theobromine, and theophylline in rat brain and plasma after subcutaneous administration were studied. The in vivo log PS and log f(u,brain) calculated using a physiologically based pharmacokinetic model correlates with in situ log PS (R(2) = 0.83) and in vitro log f(u,brain) (R(2) = 0.69), where the in situ PS and in vitro f(u,brain) was determined using in situ brain perfusion and equilibrium dialysis using brain homogenate, respectively. The time to achieve brain equilibrium can be quantitated with a proposed parameter, intrinsic brain equilibrium half-life [t(1/2eq,in) = V(b)ln2/(PS . f(u,brain))], where V(b) is the physiological volume of brain. The in vivo log t(1/2eq,in) does not correlate with in situ log PS (R(2) < 0.01) but correlates inversely with log(PS . f(u,brain)) (R(2) = 0.85). The present study demonstrates that rapid brain equilibration requires a combination of high BBB permeability and low brain tissue binding. A high BBB permeability alone cannot guarantee a rapid equilibration. The strategy to select compounds with rapid brain equilibration in drug discovery should identify compounds with high BBB permeability and low nonspecific binding in brain tissue.
authors.affiliation: Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Groton, CT 06340, USA. xingrong.liu@pfizer.com
authors.forename: Xingrong
authors.initials: X
authors.lastname: Liu
authors.forename: Bill J
authors.initials: BJ
authors.lastname: Smith
authors.forename: Cuiping
authors.initials: C
authors.lastname: Chen
authors.forename: Ernesto
authors.initials: E
authors.lastname: Callegari
authors.forename: Stacey L
authors.initials: SL
authors.lastname: Becker
authors.forename: Xi
authors.initials: X
authors.lastname: Chen
authors.forename: Julie
authors.initials: J
authors.lastname: Cianfrogna
authors.forename: Angela C
authors.initials: AC
authors.lastname: Doran
authors.forename: Shawn D
authors.initials: SD
authors.lastname: Doran
authors.forename: John P
authors.initials: JP
authors.lastname: Gibbs
authors.forename: Natilie
authors.initials: N
authors.lastname: Hosea
authors.forename: Jianhua
authors.initials: J
authors.lastname: Liu
authors.forename: Frederick R
authors.initials: FR
authors.lastname: Nelson
authors.forename: Mark A
authors.initials: MA
authors.lastname: Szewc
authors.forename: Jeffery
authors.initials: J
authors.lastname: Van Deusen
mesh_terms: D000818:Animals; D001798:Blood Proteins / Q000378:metabolism*; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism*; D006207:Half-Life; D008297:Male; D008954:Models, Biological; D010539:Permeability; D010599:Pharmacokinetics; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
chemical_list: D001798:Blood Proteins